AARHUS, Denmark--(BUSINESS WIRE)--Today CLC bio, the global leader in commercial sequence analysis software, announced that the J. Craig Venter Institute (JCVI) has extended their site license agreement with CLC bio through 2017.
“JCVI was one of our first site license deals with a premier institution in the genomics research field, and we’re proud to announce it has been extended for another five years.”
JCVI has been utilizing CLC bio’s enterprise platform since 2009 and currently uses it on more than 30 research grants, including their work as part of the Human Microbiome Project (HMP). The HMP is a National Institutes of Health-funded project to catalogue and characterize the microbes living in and on the human body. Recently, the HMP Consortium published a series of papers with results from this work in Nature and PLOSone. CLC’s bio software was used in the analysis of this work.
”The complexity and diversity of our research projects necessitates unique tools to analyze these increasingly large data sets. In our pursuit of excellence we always test and employ the best available tools for our research projects. As such we’re happy to announce the extension of our site license with CLC bio through 2017,” stated Karen Nelson, Ph.D., President, JCVI.
“For us, it’s always very exciting to see the results of all the intriguing research that our customers are doing, and no less so, when JCVI published their papers on the HMP project this summer” elaborates CEO at CLC bio, Thomas Knudsen, adding, "JCVI was one of our first site license deals with a premier institution in the genomics research field, and we’re proud to announce it has been extended for another five years."
The original 4-year site license agreement between JCVI and CLC bio was signed in the summer of 2009, and has now been extended by another 5 years, through 2017. JCVI deploys CLC bio’s platform in an integrated environment across multiple geographical locations and together with international collaborators.
About CLC bio